ATE205854T1 - Peptide als amylin-agonisten und ihre verwendung - Google Patents

Peptide als amylin-agonisten und ihre verwendung

Info

Publication number
ATE205854T1
ATE205854T1 AT92924442T AT92924442T ATE205854T1 AT E205854 T1 ATE205854 T1 AT E205854T1 AT 92924442 T AT92924442 T AT 92924442T AT 92924442 T AT92924442 T AT 92924442T AT E205854 T1 ATE205854 T1 AT E205854T1
Authority
AT
Austria
Prior art keywords
pro
ser
thr
asn
leu
Prior art date
Application number
AT92924442T
Other languages
English (en)
Inventor
Laura S L Gaeta
Howard Jones
Elisabeth Albrecht
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE205854T1 publication Critical patent/ATE205854T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT92924442T 1991-11-19 1992-11-19 Peptide als amylin-agonisten und ihre verwendung ATE205854T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79426691A 1991-11-19 1991-11-19
PCT/US1992/009842 WO1993010146A1 (en) 1991-11-19 1992-11-19 Amylin agonist peptides and uses therefor

Publications (1)

Publication Number Publication Date
ATE205854T1 true ATE205854T1 (de) 2001-10-15

Family

ID=25162163

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92924442T ATE205854T1 (de) 1991-11-19 1992-11-19 Peptide als amylin-agonisten und ihre verwendung

Country Status (17)

Country Link
EP (2) EP1162207A1 (de)
JP (4) JP2902115B2 (de)
AT (1) ATE205854T1 (de)
AU (1) AU714439B2 (de)
CA (1) CA2100745C (de)
CZ (1) CZ288029B6 (de)
DE (1) DE69232064T2 (de)
DK (1) DK0567626T3 (de)
ES (1) ES2161697T3 (de)
FI (1) FI118601B (de)
GR (1) GR3036794T3 (de)
HK (1) HK1041891A1 (de)
MD (1) MD960317A (de)
NO (2) NO324405B1 (de)
RU (1) RU2130463C1 (de)
SK (1) SK88793A3 (de)
WO (1) WO1993010146A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5625032A (en) * 1993-07-21 1997-04-29 Amylin Pharmaceuticals, Inc. Selective amylin antagonist peptides and uses therefor
CN1134110A (zh) 1993-09-07 1996-10-23 安米林药品公司 调节胃肠动力的方法
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US5739106A (en) * 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7101853B2 (en) * 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US7910548B2 (en) 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
JP4353544B2 (ja) * 1998-01-09 2009-10-28 アミリン・ファーマシューティカルズ，インコーポレイテッド アミリン作動薬ペプチド用製剤
GB0128583D0 (en) 2001-11-28 2002-01-23 Rsr Ltd Detection of autoantibodies indicative of diabetes
AU2003278929A1 (en) 2002-10-18 2004-05-13 Amylin Pharmaceuticals, Inc. Treatment of pancreatitis with amylin
WO2004083243A1 (en) * 2003-03-18 2004-09-30 Applied Research Systems Ars Holding N.V. Amylin aggregation inhibitors and use thereof.
BRPI0518390A2 (pt) * 2004-10-26 2008-11-18 Lonza Ag mÉtodo de sÍntese de peptÍdeo, e respectivo peptÍdeo
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
ATE427759T1 (de) 2004-11-01 2009-04-15 Amylin Pharmaceuticals Inc Behandlung von fettsucht und verbundenen erkrankungen
KR101383493B1 (ko) 2005-03-31 2014-04-11 아스트라제네카 파마수티컬스 엘피 정신의학적 질환 및 장애를 치료하기 위한 아밀린 및아밀린 효능제
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
NZ574710A (en) 2006-09-07 2012-02-24 Nycomed Gmbh Combination treatment comprising the PDE4 inhibitor Compound A ((2R,4aR, 10bR)6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1 ,2,3,4,4a,10b-hexahydrophenanthridin-2-ol) for diabetes mellitus
EP2120985B1 (de) 2007-02-05 2012-06-27 Amylin Pharmaceuticals, Inc. FN-38 Peptide zur Verwendung bei der Behandlung Psychotischer- und Angsterkrankungen
JP2009149684A (ja) * 2009-03-11 2009-07-09 Amylin Pharmaceut Inc アミリン作動薬ペプチド用製剤
EP2405934B1 (de) 2009-03-12 2014-03-26 Nordic Bioscience A/S Behandlung von Diabetes und metabolischem Syndrom
AR097701A1 (es) * 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
KR20160094956A (ko) 2013-11-05 2016-08-10 벤-구리온 유니버시티 오브 더 네게브 리서치 앤드 디벨럽먼트 어쏘러티 당뇨병 및 당뇨병으로부터 발생하는 합병증 질환의 치료를 위한 화합물
US10072060B2 (en) 2014-05-02 2018-09-11 The Research Foundation For The State University Of New York Islet amyloid polypeptides with improved solubility
EP3271381B1 (de) 2015-03-18 2021-09-08 Zealand Pharma A/S Amylin-analoga
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues
WO2018144671A1 (en) 2017-02-01 2018-08-09 The Research Foundation For The State University Of New York Mutant islet amyloid polypeptides with improved solubility and methods for using the same
KR102130354B1 (ko) * 2019-08-14 2020-07-06 엘아이지넥스원 주식회사 코어 제거용 이형장치
US20240335513A1 (en) 2022-05-30 2024-10-10 Zealand Pharma A/S Liquid formulations of amylin analogues
WO2024061919A1 (en) 2022-09-19 2024-03-28 Zealand Pharma A/S Combination therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
AU631112B2 (en) * 1988-01-11 1992-11-19 Amylin Corporation Treatment of type 2 diabetes mellitus
ATE128032T1 (de) * 1989-07-10 1995-10-15 Amylin Pharmaceuticals Inc Verwendung eines amylinantagonisten zur herstellung eines artzneimittels zur behandlung von fettsucht und essentieller hypertonie und damit zusammenhängenden krankheiten.
US5234906A (en) * 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
WO1992015317A1 (en) * 1991-03-08 1992-09-17 Amylin Pharmaceuticals, Inc. Synthetic preparation of amylin and amylin analogues

Also Published As

Publication number Publication date
FI933252A0 (fi) 1993-07-16
AU3075392A (en) 1993-06-15
AU1245697A (en) 1997-03-27
NO932603L (no) 1993-09-17
ES2161697T3 (es) 2001-12-16
FI118601B (fi) 2008-01-15
EP0567626B1 (de) 2001-09-19
FI933252A (fi) 1993-08-23
SK88793A3 (en) 1994-12-07
NO932603D0 (no) 1993-07-19
HK1041891A1 (zh) 2002-07-26
JP2902115B2 (ja) 1999-06-07
CA2100745C (en) 2007-07-31
EP1162207A1 (de) 2001-12-12
WO1993010146A1 (en) 1993-05-27
GR3036794T3 (en) 2002-01-31
AU714439B2 (en) 2000-01-06
RU2130463C1 (ru) 1999-05-20
AU673147B2 (en) 1996-10-31
CA2100745A1 (en) 1993-05-20
MD960317A (ro) 1998-05-31
JP2006213716A (ja) 2006-08-17
NO324405B1 (no) 2007-10-08
DE69232064D1 (de) 2001-10-25
DK0567626T3 (da) 2001-12-17
EP0567626A1 (de) 1993-11-03
JP2003238594A (ja) 2003-08-27
CZ288029B6 (cs) 2001-04-11
JP4018116B2 (ja) 2007-12-05
CZ168993A3 (en) 1994-04-13
NO20073265L (no) 1993-09-17
DE69232064T2 (de) 2002-03-28
JPH11152299A (ja) 1999-06-08
JPH06504794A (ja) 1994-06-02

Similar Documents

Publication Publication Date Title
ATE205854T1 (de) Peptide als amylin-agonisten und ihre verwendung
DE10075019I1 (de) Neue Proteine mit TNF-Hemmender wirkung und ihre Herstellung.
DE3750197D1 (de) Antagonisten des Fibroblasten-Wachstumsfaktors.
IL89541A0 (en) Urethane-protected amino acid-n-carboxyanhydrides and their use in the synthesis of polypeptides
WO1995030750A8 (fr) Fractions polypeptidiques solubles de la proteine lag-3; procede de production; composition therapeutique; anticorps anti-idiotype
ATE81779T1 (de) Peptidanalogedes insulinaehnlichen wachstumsfaktors-1 bei saeugetieren.
CA2094027A1 (en) Osteogenic peptides
ES2054365T3 (es) Inhibicion de la via de la regla del n final en celulas vivas.
DK0863155T3 (da) Suppression af T-celle-proliferation under anvendelse af peptidfragmenter af myelin basisk protein
ES489522A0 (es) Un procedimiento para la preparacion de un polipeptido
GB8821785D0 (en) Peptide compounds
Nitta et al. Primary structure of a ribonuclease from bullfrog (Rana catesbeiana) liver
Huang et al. An antiplatelet peptide, gabonin, from Bitis gabonica snake venom
EP0292257A3 (de) Peptide mit ANF-Wirksamkeit
WO1999048908A3 (fr) POLYPEPTIDE IMMUNOREACTIF DU RECEPTEUR TrkA du NGF ET UTILISATIONS
ATE124955T1 (de) Substrat-peptide.
ES2044928T3 (es) Enzima alfa-amidante en terminal c y procedimiento para la produccion y el uso del mismo.
CA2083286A1 (en) Recombinant fibrinogenases, preparation and use thereof
EP0687685A4 (de) Physiologisch-aktive peptide
DK200200302A (da) Rekombinante polypeptider omfattende aminosyresekvensen af moden vævsfaktorinhibitor (TFI), polypeptidfragmenter deraf, ekspressionsvektorer der koder for disse, værtsceller transformeret dermed, og fremgangsmåde til fremstilling af et ........
ES2051152B1 (es) Procedimiento de sistesis de peptidos con capacidad de detectar anticuerpos anti-virus de la hepatitis c (vhc) en suero de individuos afectados.
ES2069476A1 (es) Procedimiento de sintesis de peptidos con capacidad de detectar anticuerpos ant-virus de la hepatitis c (vhc) en suero de individuos afectados.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification